Greg operates at the intersection of corporate strategy, commercial execution, and enterprise AI, advising biopharma executive teams at the moments where the quality of decisions directly determines enterprise growth, asset value, and time for medicines to reach patients. His perspectives and engagements with clients over the past decade tackled complex challenges and high leverage opportunities across biopharma strategy.​

At Scimitar, Greg serves as Principal and spearheads the firm’s AI and Digital practice, partnering with clients to translate AI ambition into measurable, compounding enterprise value. He is also a member of Scimitar’s Commercial Leadership team. His work spans the full biopharma value chain: portfolio and pipeline strategy and planning, AI design and implementation, new product planning, launch strategy and organizational design, M&A and transaction diligence, and operating model transformation across oncology, rare disease, neurology, and cardiology. ​

His previous experiences at L.E.K. Consulting, Blue Matter, EVERSANA, FundRx, and Perelman School of Medicine’s Department of Neurosurgery brings a cross-disciplinary background across strategy and management consulting, venture investing, and translational research. These experiences have shaped his analytical rigor and pragmatic execution across his work.